Hospital Sierrallana-ko ikertzaileekin lankidetzan egindako argitalpenak (18)

2023

  1. A novel clinical sign to assess the risk of Parkinson’s disease in patients with isolated asymmetric arm swing

    Neurological Sciences, Vol. 44, Núm. 4, pp. 1401-1404

  2. Interactions between functional networks in Parkinson's disease mild cognitive impairment

    Scientific Reports, Vol. 13, Núm. 1

  3. Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

    Frontiers in Immunology, Vol. 14

2022

  1. Neurogenetic traits outline vulnerability to cortical disruption in Parkinson's disease

    NeuroImage: Clinical, Vol. 33

  2. Teriflunomide-induced Raynaud’s phenomenon: a serious adverse event, previously unreported

    Neurological Sciences

2021

  1. Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1269-1278

  2. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

    Frontiers in Immunology, Vol. 12

  3. Predictive value of prolactin in first episode psychosis at ten years follow-up

    Revista de Psiquiatria y Salud Mental, Vol. 14, Núm. 3, pp. 179-180

2020

  1. A novel SGCE variant is associated with myoclonus-dystonia with phenotypic variability

    Neurological Sciences, Vol. 41, Núm. 12, pp. 3779-3781

  2. Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats (Psychopharmacology, (2020), 237, 8, (2419-2431), 10.1007/s00213-020-05544-6)

    Psychopharmacology

  3. Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders

    Parkinsonism and Related Disorders, Vol. 70, pp. 74-81

  4. Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease

    Movement Disorders, Vol. 35, Núm. 2, pp. 316-325

  5. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats

    Psychopharmacology, Vol. 237, Núm. 8, pp. 2419-2431

  6. Nonpharmacological, nonsurgical treatments for freezing of gait in Parkinson's disease: A systematic review

    Movement Disorders, Vol. 35, Núm. 2, pp. 204-214

2019

  1. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 10, pp. 2065-2076

  2. Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients

    Archives of Women's Mental Health, Vol. 22, Núm. 3, pp. 367-373

2018

  1. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study

    Movement Disorders, Vol. 33, Núm. 11, pp. 1809-1813

2017

  1. Bone Health in Parkinson’s Disease

    Clinical Reviews in Bone and Mineral Metabolism, Vol. 15, Núm. 3, pp. 99-114